Appointment dossier — Neuroblastoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Neuroblastoma
- Genistein — Review evidence · 1 positive · PMID 42133114
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT06988475 · Phase 2 / Phase 3 — DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations (United Kingdom)
- NCT05770037 · Phase 2 / Phase 3 — DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers (United Kingdom)
- NCT03126916 · Phase 3 — Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (United States)
- NCT07375563 · Phase 3 — Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma (Russia)
- NCT04706910 · Phase 3 — 18F-DOPA II - PET Imaging Optimization (Canada)
- NCT06803875 · Phase 1 / Phase 2 — Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma (United States)
- NCT07334301 · Phase 1 / Phase 2 — A Multi-Arm, Platform Trial For Relapsed Neuroblastoma (Australia)
- NCT06541262 · Phase 1 / Phase 2 — Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors (United States)
- NCT00107289 · Phase 2 — Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma (United States)
- NCT05754684 · Phase 2 — Quadruple Immunotherapy for Neuroblastoma (Hong Kong)
- NCT07537400 · Phase 2 — Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5 (Israel)
- NCT06255210 · Phase 2 — Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON) (China)
- NCT04936529 · Phase 2 — A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma (United States)
- NCT06814496 · Phase 1 / Phase 2 — Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (United States)
- NCT06721689 · Phase 1 / Phase 2 — PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors (United States)
- NCT07635056 · Phase 2 — Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma (United States)
- NCT06500819 · Phase 1 — Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors (United States)
- NCT02013336 · Phase 1 — Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors (United States)
Most-relevant first: trials that name Neuroblastoma, then broader trials you may still qualify for. 108 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT06988475), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?